We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 30, 2017

Daratumumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma



Additional Info

Disclosure statements are available on the authors' profiles:

Daratumumab Plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Blood 2017 Jun 21;[EPub Ahead of Print], A Chari, A Suvannasankha, JW Fay, B Arnulf, JL Kaufman, JJ Ifthikharuddin, BM Weiss, A Krishnan, S Lentzsch, R Comenzo, J Wang, K Nottage, C Chiu, NZ Khokhar, T Ahmadi, S Lonial

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading